JP2016528202A - 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用 - Google Patents

小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用 Download PDF

Info

Publication number
JP2016528202A
JP2016528202A JP2016524930A JP2016524930A JP2016528202A JP 2016528202 A JP2016528202 A JP 2016528202A JP 2016524930 A JP2016524930 A JP 2016524930A JP 2016524930 A JP2016524930 A JP 2016524930A JP 2016528202 A JP2016528202 A JP 2016528202A
Authority
JP
Japan
Prior art keywords
vegf antagonist
vegf
dose
child
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528202A5 (2
Inventor
アクゼノヴ，セルゲイ
ブリアン，ガブリエラ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016528202A publication Critical patent/JP2016528202A/ja
Publication of JP2016528202A5 publication Critical patent/JP2016528202A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2016524930A 2013-07-11 2014-07-09 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用 Pending JP2016528202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845064P 2013-07-11 2013-07-11
US61/845,064 2013-07-11
PCT/IB2014/062978 WO2015004616A1 (en) 2013-07-11 2014-07-09 Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients

Publications (2)

Publication Number Publication Date
JP2016528202A true JP2016528202A (ja) 2016-09-15
JP2016528202A5 JP2016528202A5 (2) 2017-08-10

Family

ID=51211282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524930A Pending JP2016528202A (ja) 2013-07-11 2014-07-09 小児患者の脈絡網膜血管新生障害および透過性障害の治療におけるｖｅｇｆアンタゴニストの使用

Country Status (11)

Country Link
US (2) US20160168240A1 (2)
EP (1) EP3019526A1 (2)
JP (1) JP2016528202A (2)
KR (1) KR20160029794A (2)
CN (1) CN105377891A (2)
AU (2) AU2014288837A1 (2)
BR (1) BR112016000177A2 (2)
CA (1) CA2917807A1 (2)
MX (1) MX2016000384A (2)
RU (1) RU2676274C2 (2)
WO (1) WO2015004616A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022184907A (ja) * 2017-05-01 2022-12-13 オーハイ レチナル テクノロジー，エルエルシー 近視の治療のためのシステムおよびプロセス

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
RU2702748C2 (ru) * 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
CN108290004A (zh) * 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017197199A1 (en) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
US20190388522A1 (en) * 2017-01-25 2019-12-26 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
WO2019099786A1 (en) * 2017-11-16 2019-05-23 Ophthotech Corporation A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
PL3886858T3 (pl) * 2019-12-19 2022-08-29 Active Biotech Ab Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem
RU2762991C1 (ru) * 2021-09-06 2021-12-24 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
TW202525324A (zh) * 2023-08-17 2025-07-01 大陸商信達生物製藥（蘇州）有限公司 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法
CN118085112B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗多个vegf家族蛋白的融合蛋白及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
JP2012512184A (ja) * 2008-12-16 2012-05-31 キュー エル ティー インク． 眼の状態に関する光線力学的療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
KR100897379B1 (ko) 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
JP2012512184A (ja) * 2008-12-16 2012-05-31 キュー エル ティー インク． 眼の状態に関する光線力学的療法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACTA OPHTHALMOL., vol. 90, no. 7, JPN5016007785, 17 February 2012 (2012-02-17), pages 574 - 575, ISSN: 0003999946 *
ARCH OPHTHALMOL., vol. 126, no. 8, JPN6018015030, 2008, pages 1152 - 1156, ISSN: 0003999947 *
CAN. J. OPHTHALMOL., vol. 46, no. 1, JPN5016007788, 1 February 2011 (2011-02-01), pages 46 - 50, ISSN: 0003999949 *
J. AAPOS, vol. 13, no. 6, JPN5016007787, 1 December 2009 (2009-12-01), pages 616 - 617, ISSN: 0003999948 *
LUCENTIS (RANIBIZUMAB INJECTION) INTRAVITREAL INJECTION (LABEL), JPN6018015031, 2012, pages 6 - 14, ISSN: 0003999950 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022184907A (ja) * 2017-05-01 2022-12-13 オーハイ レチナル テクノロジー，エルエルシー 近視の治療のためのシステムおよびプロセス

Also Published As

Publication number Publication date
RU2016104397A (ru) 2017-08-16
EP3019526A1 (en) 2016-05-18
CA2917807A1 (en) 2015-01-15
US20180194835A1 (en) 2018-07-12
WO2015004616A1 (en) 2015-01-15
BR112016000177A2 (pt) 2017-12-12
RU2016104397A3 (2) 2018-05-31
AU2017203923B2 (en) 2018-10-18
AU2014288837A1 (en) 2015-12-10
US20160168240A1 (en) 2016-06-16
KR20160029794A (ko) 2016-03-15
AU2017203923A1 (en) 2017-07-06
MX2016000384A (es) 2016-04-29
RU2676274C2 (ru) 2018-12-27
CN105377891A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
AU2017203923B2 (en) Use of a VEGF antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
JP7668858B2 (ja) チロシンキナーゼ阻害剤を含む眼内インプラント
Zhang et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys
JP2016523956A (ja) 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
JP2015528454A (ja) 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
JP2016522249A (ja) 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
JP2016522248A (ja) ポリープ状脈絡膜血管症の治療
JP7828274B2 (ja) 眼疾患を治療するための方法
JP2026072102A (ja) 眼疾患を治療するための方法
Ansari et al. Diabetic Eye Diseases
BR112022018815B1 (pt) Implante ocular contendo um inibidor de tirosina cinase, seus métodos de preparação, e usos
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190319